Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

25.34
+0.86003.51%
Post-market: 25.980.6400+2.53%19:09 EDT
Volume:2.18M
Turnover:54.54M
Market Cap:3.18B
PE:-7.84
High:25.48
Open:24.45
Low:24.13
Close:24.48
52wk High:28.72
52wk Low:7.91
Shares:125.35M
Float Shares:88.65M
Volume Ratio:3.11
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2326
EPS(LYR):-3.2900
ROE:-69.95%
ROA:-23.11%
PB:6.06
PE(LYR):-7.70

Loading ...

Arcus Biosciences grants new-hire equity awards for 25,600 shares under 2020 Inducement Plan

Reuters
·
Mar 10

Arcus Biosciences Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 06

Arcus Biosciences price target raised to $45 from $44 at Citi

TIPRANKS
·
Mar 05

Evercore ISI Sticks to Their Buy Rating for Arcus Biosciences (RCUS)

TIPRANKS
·
Mar 03

Arcus Biosciences Up Over 19%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk

Dow Jones
·
Mar 03

Stock Track | Arcus Biosciences Soars 5.55% Intraday on Analyst Price Target Hikes

Stock Track
·
Mar 02

H.C. Wainwright Remains a Buy on Arcus Biosciences (RCUS)

TIPRANKS
·
Mar 02

Arcus Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 02

Arcus Biosciences price target raised to $49 from $36 at Leerink

TIPRANKS
·
Mar 02

Arcus Biosciences to Present at Leerink Global Healthcare Conference 2026

Reuters
·
Feb 27

Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

TIPRANKS
·
Feb 26

BRIEF-Arcus Biosciences Files For Mixed Shelf

Reuters
·
Feb 26

Arcus Biosciences Q4 net loss USD 106 million, up 12.8%

Reuters
·
Feb 26

BRIEF-Arcus Biosciences Q4 Operating Expenses USD 147 Million

Reuters
·
Feb 26

Arcus Biosciences Inc - Has $1.0 Bln Cash, Runway Until Second Half of 2028

THOMSON REUTERS
·
Feb 26

Arcus Biosciences’ casdatifan shows increased survival in kidney cancer

TIPRANKS
·
Feb 24

Arcus reports 15.1-month median PFS for casdatifan in late-line kidney cancer ARC-20 study

Reuters
·
Feb 24

Arcus Biosciences to Present Casdatifan Phase 1/1b ARC-20 Kidney Cancer Data at ASCO GU Cancer Symposium

Reuters
·
Feb 24

Wells Fargo Downgrades Arcus Biosciences to Equal Weight From Overweight, Adjusts PT to $23 From $30

MT Newswires Live
·
Feb 12

Arcus Biosciences Inc : Wells Fargo Cuts to Equal Weight From Overweight

THOMSON REUTERS
·
Feb 12